Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 08, 2025 08:30 ET | Source: Oncotelic Therapeutics, Inc.

Sapu Nano Unveils First-in-Human Clinical Trial of Sapu-003 at 8th Australian Translational Breast Cancer Research Symposium

SYDNEY, Australia, Oct. 08, 2025 (GLOBE NEWSWIRE) -- via IBN – Sapu Nano today announced the presentation of its poster, “Sapu-003: Novel Intravenous Deciparticle™ Everolimus Entering Phase 1 Study...
September 24, 2025 20:11 ET | Source: Sapu Biosciences, LLC

Sapu Nano’s Sapu003 Advances to Human Clinical Testing - Transforming Everolimus Delivery with Full Bioavailability for Breast Cancer Patients

Sapu003 Designed to Overcome Limitations of Afinitor®, FDA-Approved Oral Everolimus, Delivering Full Strength of Everolimus via Intravenous Injection AUSTRALIA, Sydney, Sept. 24, 2025 (GLOBE...
September 24, 2025 20:00 ET | Source: Sapu Biosciences, LLC

Sapu Nano’s Sapu003 Advances to Human Clinical Testing - Transforming Everolimus Delivery with Full Bioavailability for Breast Cancer Patients

Sapu003 Designed to Overcome Limitations of Afinitor®, FDA-Approved Oral Everolimus, Delivering Full Strength of Everolimus via Intravenous Injection AUSTRALIA, Sydney, Sept. 24, 2025 (GLOBE...
September 24, 2025 08:30 ET | Source: Oncotelic Therapeutics, Inc.

Sapu Nano’s Sapu003 Advances to Human Clinical Testing - Transforming Everolimus Delivery with Full Bioavailability for Breast Cancer Patients

SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- via IBN -- Sapu Nano, developer of Deciparticle™, today announced that it has received approval from Australia’s Human Research Ethics Committee (HREC)...